Suneva Medical, a privately held aesthetics company, has acquired an aesthetic product portfolio from Spear Pharmaceuticals. Under the terms of the agreement, Suneva will acquire worldwide rights to Refissaa .05% tretinoin cream and its marketed generic equivalent. Financial terms were not disclosed.
“This acquisition is very significant for Suneva on several levels. We are entering the prescription topical aesthetic market, a potential $100 million market opportunity, with a unique basket of products including Refissa,” said Nick Teti, chairman and CEO of Suneva Medical. “This deal also allows us to offer aesthetic physicians a comprehensive anti-aging solution, which includes our ReGenica skincare line, Refissa, the gold standard topical treatment for fine lines and hyperpigmentation and our novel injectable filler, Artefill. This acquisition promises to be a transformational event for the Company.”